| |
|
VGX Pharmaceuticals Announces Research
Collaboration with the University of Pennsylvania |
BLUE BELL, P.A. – December 22, 2OO5 –
VGX Pharmaceuticals today announced that it has entered a research agreement
with the University of Pennsylvania whereby the company will provide financial
support over the next five years for further viral protein research and
other selected research programs.
This commitment is a logical extension of other research and development
activities that VGX has in the area of viral proteins and their ability
to control certain host cell functions. The agreement further extends
the important relationship that the company enjoys with the University
of Pennsylvania.
“We are excited about creating a broader and more comprehensive
research alliance with the University of Pennsylvania and look forward
to the prospects of additional novel discoveries in the area of viral
proteins. This area of research forms an important part of our development
portfolio, and demonstrates the company’s confidence in Penn’s
research capabilities ” said J. Joseph Kim, Ph.D., President and
CEO of VGX Pharmaceuticals.
The VGX sponsored research programs at the University of Pennsylvania
will be conducted under the direction of Professor David B. Weiner, Ph.D.
Professor Weiner is a world-renowned leader in viral pathology and genomics,
and is a pioneer in the field of DNA vaccines to treat infectious diseases
and cancer as well as a co-founder of VGX Pharmaceuticals.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About VGX Pharmaceuticals
VGX Pharmaceuticals is a biopharmaceutical company with product candidates
for the treatment of infectious diseases including HIV, hepatitis C as well
as cancer and inflammatory diseases. The Company’s clinical development
programs include PICTOVIR™ for HIV infection and VGX-410C for chronic
hepatitis C infection that are currently in Phase II clinical trials. In
addition, VGX Pharmaceuticals’ therapeutic platform is designed to
advance a strong and continual pipeline of drug candidates into the clinic
with novel product candidates to treat cancer and inflammatory diseases.
The product candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Vice President
Tel 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
